Pouchitis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects With Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis
A Phase III, multi-centre, double-blind randomised controlled trial in subjects with chronic
antibiotic refractory pouchitis.
Subjects will undertake a <2 week screening period to provide baseline data and be assessed
for eligibility. At the Baseline visit (Day 1) eligible subjects will be randomised on a 1:1
basis to either a) 240 mg alicaforsen enema or b) matching placebo.
Study drug will be administered once nightly (on going to bed) up to and including week 6.
Following the Day 1 Visit, subjects will return to the clinic for safety and efficacy
assessments at Week 3, 6, 10, 18 and 26.
Subjects may receive certain permitted medications as per Entry Criteria, which must remain
at stable doses throughout the trial. Introduction of any new medication for pouchitis, or a
dose change to an existing concomitant medication for pouchitis, other than those detailed in
the protocol, will not be permitted.
Clinical symptoms associated with pouchitis will be recorded daily by the patient in a diary
card.
Subjects will undergo endoscopic examination of their pouch (during Screening, and at Weeks 6
and 10). Where technically feasible, each endoscopy will provide at least one biopsy sample
for histopathology.
In addition to endoscopic, histopathologic and symptomatic assessments, Quality of Life will
be assessed.
Bloods for routine assessment, including haematology and biochemistry will be taken. Bloods
and stool samples will be collected to evaluate relevant biomarkers.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04979832 -
GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05829109 -
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
|
Early Phase 1 | |
| Recruiting |
NCT03136419 -
Microbiota and Immune microEnvironment in Pouchitis
|
N/A | |
| Withdrawn |
NCT04640155 -
Treating Chronic Pouchitis With a Low FODMAP Diet
|
N/A | |
| Completed |
NCT02201186 -
To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis
|
Phase 2 | |
| Completed |
NCT02790138 -
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
|
Phase 4 | |
| Not yet recruiting |
NCT01202396 -
The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis
|
N/A | |
| Completed |
NCT02428361 -
Fecal Microbiota Transplant (FMT) for Pouchitis
|
Early Phase 1 | |
| Completed |
NCT03538366 -
Fecal Microbiota Transplantation for Chronic Pouchitis
|
N/A | |
| Completed |
NCT04763564 -
Efficacy of Liraglutide Therapy in Patients With IPAA
|
Phase 2 | |
| Terminated |
NCT00583531 -
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
|
Phase 2 | |
| Recruiting |
NCT03524352 -
the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
|
Phase 3 | |
| Completed |
NCT04820413 -
Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis
|
N/A | |
| Not yet recruiting |
NCT06443502 -
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
|
Phase 3 | |
| Recruiting |
NCT04089345 -
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
|
Phase 3 | |
| Not yet recruiting |
NCT03526796 -
Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis
|
N/A | |
| Terminated |
NCT02782325 -
Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)
|
Phase 1/Phase 2 | |
| Completed |
NCT02828410 -
Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA
|
N/A | |
| Recruiting |
NCT05578313 -
Inflammatory Bowel Diseases (IBD) Cannabis Registry
|